- Home
- LYRA vs BRTX Comparison
LYRA vs BRTX Comparison
Compare LYRA & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYRA
- BRTX
- Stock Information
- Founded
- LYRA 2005
- BRTX 1997
- Country
- LYRA United States
- BRTX United States
- Employees
- LYRA N/A
- BRTX N/A
- Industry
- LYRA Medical/Dental Instruments
- BRTX Managed Health Care
- Sector
- LYRA Health Care
- BRTX Health Care
- Exchange
- LYRA Nasdaq
- BRTX Nasdaq
- Market Cap
- LYRA 15.0M
- BRTX 12.6M
- IPO Year
- LYRA 2020
- BRTX N/A
- Fundamental
- Price
- LYRA $9.40
- BRTX $1.61
- Analyst Decision
- LYRA Buy
- BRTX Strong Buy
- Analyst Count
- LYRA 2
- BRTX 1
- Target Price
- LYRA $16.00
- BRTX $18.00
- AVG Volume (30 Days)
- LYRA 1.9M
- BRTX 253.7K
- Earning Date
- LYRA 08-13-2025
- BRTX 08-12-2025
- Dividend Yield
- LYRA N/A
- BRTX N/A
- EPS Growth
- LYRA N/A
- BRTX N/A
- EPS
- LYRA N/A
- BRTX N/A
- Revenue
- LYRA $1,185,000.00
- BRTX $391,000.00
- Revenue This Year
- LYRA N/A
- BRTX $391.52
- Revenue Next Year
- LYRA $1,286.17
- BRTX $3.50
- P/E Ratio
- LYRA N/A
- BRTX N/A
- Revenue Growth
- LYRA N/A
- BRTX 161.54
- 52 Week Low
- LYRA $3.81
- BRTX $1.21
- 52 Week High
- LYRA $37.50
- BRTX $2.55
- Technical
- Relative Strength Index (RSI)
- LYRA 45.31
- BRTX 46.78
- Support Level
- LYRA $10.15
- BRTX $1.57
- Resistance Level
- LYRA $14.88
- BRTX $1.72
- Average True Range (ATR)
- LYRA 2.03
- BRTX 0.13
- MACD
- LYRA -0.67
- BRTX -0.01
- Stochastic Oscillator
- LYRA 0.42
- BRTX 20.65
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.